Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Oncoimmunology

Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P.
PMID: 28405498
Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017.

We developed cergutuzumab amunaleukin (CEA-IL2v, RG7813), a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembryonic antigen (CEA)-specific antibody devoid of Fc-mediated...

Cite
Klein C, Waldhauer I, Nicolini VG, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017;6(3):e1277306doi: 10.1080/2162402X.2016.1277306.
Klein, C., Waldhauer, I., Nicolini, V. G., Freimoser-Grundschober, A., Nayak, T., Vugts, D. J., Dunn, C., Bolijn, M., Benz, J., Stihle, M., Lang, S., Roemmele, M., Hofer, T., van Puijenbroek, E., Wittig, D., Moser, S., Ast, O., Brünker, P., Gorr, I. H., Neumann, S., de Vera Mudry, M. C., Hinton, H., Crameri, F., Saro, J., Evers, S., Gerdes, C., Bacac, M., van Dongen, G., Moessner, E., & Umaña, P. (2017). Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology, 6(3), e1277306. https://doi.org/10.1080/2162402X.2016.1277306
Klein, Christian, et al. "Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines." Oncoimmunology vol. 6,3 (2017): e1277306. doi: https://doi.org/10.1080/2162402X.2016.1277306
Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017. PMID: 28405498; PMCID: PMC5384349.
Copy Download .nbib Format: NLM
Morphologic and functional effects of gamma secretase inhibition on splenic marginal zone B cells.

International journal of Alzheimer's disease

de Vera Mudry MC, Regenass-Lechner F, Ozmen L, Altmann B, Festag M, Singer T, Müller L, Jacobsen H, Flohr A.
PMID: 23316412
Int J Alzheimers Dis. 2012;2012:289412. doi: 10.1155/2012/289412. Epub 2012 Dec 17.

The γ-secretase complex is a promising target in Alzheimer's disease because of its role in the amyloidogenic processing of β-amyloid precursor protein. This enzyme also catalyzes the cleavage of Notch receptor, resulting in the nuclear translocation of intracellular Notch...

Cite
de Vera Mudry MC, Regenass-Lechner F, Ozmen L, et al. Morphologic and functional effects of gamma secretase inhibition on splenic marginal zone B cells. Int J Alzheimers Dis. 2012;2012:289412doi: 10.1155/2012/289412.
de Vera Mudry, M. C., Regenass-Lechner, F., Ozmen, L., Altmann, B., Festag, M., Singer, T., Müller, L., Jacobsen, H., & Flohr, A. (2012). Morphologic and functional effects of gamma secretase inhibition on splenic marginal zone B cells. International journal of Alzheimer's disease, 2012289412. https://doi.org/10.1155/2012/289412
de Vera Mudry, Maria Cristina, et al. "Morphologic and functional effects of gamma secretase inhibition on splenic marginal zone B cells." International journal of Alzheimer's disease vol. 2012 (2012): 289412. doi: https://doi.org/10.1155/2012/289412
de Vera Mudry MC, Regenass-Lechner F, Ozmen L, Altmann B, Festag M, Singer T, Müller L, Jacobsen H, Flohr A. Morphologic and functional effects of gamma secretase inhibition on splenic marginal zone B cells. Int J Alzheimers Dis. 2012;2012:289412. doi: 10.1155/2012/289412. Epub 2012 Dec 17. PMID: 23316412; PMCID: PMC3534238.
Copy Download .nbib Format: NLM
Showing 1 to 2 of 2 entries